加拿大脑膜炎奈瑟菌 B 群分离株的多样性和一种脑膜炎奈瑟菌 B 群候选疫苗（4CMenB）的估计保护率。
Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB).
机构信息
Vaccine Evaluation Center, BC Children's Hospital and the University of British Columbia, Vancouver V5Z4H4, Canada.
Vaccine Evaluation Center, BC Children's Hospital and the University of British Columbia, Vancouver V5Z4H4, Canada.
出版信息
Vaccine. 2013 Dec 17;32(1):124-30. doi: 10.1016/j.vaccine.2013.03.063. Epub 2013 Apr 12.
BACKGROUND
In collaboration with the Canadian Immunization Monitoring Program Active (IMPACT), the National Microbiology Laboratory, the UK Health Protection Agency and Novartis Vaccines, we tested the potential of an investigational 4-component meningococcal B vaccine (4CMenB) to cover Canadian strains circulating from 2006 to 2009.
METHODS
IMPACT meningococcal surveillance is population based and includes over 50% of Canadian adults and children. All isolates were characterized by Meningococcal Antigen Typing System (MATS) and sequencing for factor H-binding protein (fHbp), Neisseria Heparin Binding Antigen (NHBA) and Neisserial adhesin A (NadA).
RESULTS
In total, 157 isolates were tested. Overall, 4CMenB MATS predicted strain coverage was 66% (95% CI: 46-78%), with 26%, 29% and 11% of strains covered by one, two and three vaccine antigens, respectively. The coverage of each antigen was as follows: 13% PorA, 1% NadA, 52% fHbp and 51% NHBA. The majority of strains for clonal complex (cc) 41/44 and cc60 were covered by NHBA; the majority of strains for cc269 and cc32 were covered by fHbp and NHBA. Coverage for two prevalent strains (sequence type (ST)-269 and ST-154) was 95% and 100%, respectively.
CONCLUSIONS
4CMenB has the potential to protect against a significant proportion of Canadian invasive MenB strains.
背景
与加拿大免疫监测计划主动（IMPACT）、国家微生物学实验室、英国卫生保护局和诺华疫苗合作，我们测试了一种研究性的 4 组份脑膜炎 B 疫苗（4CMenB）对覆盖加拿大 2006 年至 2009 年流行菌株的潜力。
方法
IMPACT 脑膜炎监测是基于人群的，包括超过 50%的加拿大成年人和儿童。所有分离株均通过脑膜炎球菌抗原分型系统（MATS）和因子 H 结合蛋白（fHbp）、奈瑟菌肝素结合抗原（NHBA）和奈瑟菌黏附素 A（NadA）测序进行特征描述。
结果
共检测了 157 株分离株。总体而言，4CMenB MATS 预测的菌株覆盖率为 66%（95%CI：46-78%），分别有 26%、29%和 11%的菌株由一种、两种和三种疫苗抗原覆盖。各抗原的覆盖率如下：13% PorA、1% NadA、52% fHbp 和 51% NHBA。大多数 clonal complex（cc）41/44 和 cc60 菌株由 NHBA 覆盖；大多数 cc269 和 cc32 菌株由 fHbp 和 NHBA 覆盖。两种流行菌株（序列型（ST）-269 和 ST-154）的覆盖率分别为 95%和 100%。
结论
4CMenB 有可能预防加拿大侵袭性 MenB 菌株的很大一部分。
Zotero 插件